<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430947</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-CoBRIM-67</org_study_id>
    <secondary_id>2017-000768-13</secondary_id>
    <nct_id>NCT03430947</nct_id>
  </id_info>
  <brief_title>Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases</brief_title>
  <acronym>RadioCoBRIM</acronym>
  <official_title>An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open label, non-randomised study of vemurafenib and cobimetinib after&#xD;
      radiosurgery in adult patients with BRAFV600-mutant melanoma brain metastases. All patients&#xD;
      will receive vemurafenib 960 mg twice a day on days 1 - 28 combined with cobimetinib 60 mg&#xD;
      once a day on days 1 - 21 of each 28-day treatment cycle until disease progression, drug&#xD;
      toxicity or death.&#xD;
&#xD;
      The primary objective of this study is to determine the best overall response rate (BORR) in&#xD;
      the brain. The extracranial BORR, intra- and extracranial duration of response,&#xD;
      progression-free survival and overall survival, adverse events, quality of life and radiomics&#xD;
      features predicting long-term local control of brain metastases and treatment-related&#xD;
      toxicity will also be examined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response rate in the brain</measure>
    <time_frame>2 years</time_frame>
    <description>rate of patients with complete response or partial response (intracranial)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracranial best overall response rate</measure>
    <time_frame>2 years</time_frame>
    <description>rate of patients with complete response or partial response (extracranial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate calculated for the whole body tumor sites</measure>
    <time_frame>2 years</time_frame>
    <description>rate of patients with complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial duration of response</measure>
    <time_frame>2 years</time_frame>
    <description>time from best overall response in the brain to first documentation of intracranial progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial duration of response</measure>
    <time_frame>2 years</time_frame>
    <description>time from best extracranial overall response to first documentation of extracranial progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>time from first dose of study treatment until progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>time from first dose of study treatment until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03; number of patients who withdraw from the study due to intolerable adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiomics for long-term control of brain metastases</measure>
    <time_frame>every 6 weeks up to 2 years</time_frame>
    <description>Radiomics features predictive of long-term local control of brain metastases using Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiomics for intracranial Treatment-related toxicity</measure>
    <time_frame>every 6 weeks up to 2 years</time_frame>
    <description>Radiomics features predicting treatment-related toxicity (e.g. radionecrosis, hemorrhage, edema) using Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Malignant Melanoma Stage IV</condition>
  <condition>BRAF V600 Mutation</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients will be treated with Vemurafenib + Cobimetinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Female and male patients ≥ 18 years of age&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma (stage IV, per AJCC staging), carrying&#xD;
             BRAF V600-mutation&#xD;
&#xD;
          -  Performed SRS 14 ±7 days before baseline using a harmonized protocol in patients with&#xD;
             at least one measurable intracranial target lesion for which the following criteria&#xD;
             are met:&#xD;
&#xD;
               -  Previously untreated (Lesions in previously irradiated area should not be&#xD;
                  selected)&#xD;
&#xD;
               -  Largest diameter of ≥ 0.5 but ≤ 4 cm as determined by contrast-enhanced MRI and&#xD;
&#xD;
               -  ≤ 10 brain metastases&#xD;
&#xD;
          -  ECOG performance status 0 - 2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow function as indicated by the following:&#xD;
&#xD;
               -  ANC ≥ 1500/µL,&#xD;
&#xD;
               -  Platelets ≥ 100,000/µL and&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Adequate renal function, as indicated by creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Adequate liver function, as indicated by bilirubin &lt; 1.5 x ULN and AST and ALT &lt; 3 x&#xD;
             ULN (documented liver metastases: AST and ALT &lt; 5 x ULN)&#xD;
&#xD;
          -  Adequate coagulation within 28 days prior to baseline visit&#xD;
&#xD;
               -  Patients without therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN&#xD;
&#xD;
               -  Patients receiving therapeutic anticoagulation: stable anticoagulation regimen&#xD;
                  and stable INR&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Symptomatic brain metastases requiring immediate local interventions such as&#xD;
             neurosurgery or radiosurgery&#xD;
&#xD;
          -  Leptomeningeal disease (also synchronous with brain metastases)&#xD;
&#xD;
          -  Prior therapy with BRAF or MEK inhibitors within 12 weeks prior to baseline visit&#xD;
             (prior therapies for metastatic melanoma including chemo-, cytokine-, immuno-,&#xD;
             biological and vaccine-therapy will be al-lowed) A period of at least 6 weeks must be&#xD;
             observed between the last dose of ipilimumab and the first administration of the study&#xD;
             treatments. Prior treatment with anti-programmed cell death (PD)-1 or anti-PD ligand 1&#xD;
             (PD-L1) is allowed.&#xD;
&#xD;
          -  Prior whole brain irradiation (Patients with prior local therapy of brain metas-tases&#xD;
             are eligible)&#xD;
&#xD;
          -  Patients receiving therapeutic steroids are not stable on corticoster-oids 2 weeks&#xD;
             before SRS&#xD;
&#xD;
          -  Active and uncontrolled infection&#xD;
&#xD;
          -  Known HIV infection or active HBV or HCV infection&#xD;
&#xD;
               -  Active HBV infection (chronic and acute), defined as having a posi-tive hepatitis&#xD;
                  B surface antigen (HBsAg) test at screening (past or resolved HBV infection,&#xD;
                  defined as negative HBsAg test and a posi-tive total hepatitis B core antibody&#xD;
                  test at screening, are eligible)&#xD;
&#xD;
               -  Active HCV infection, defined as positive HCV antibody test and positive HCV RNA&#xD;
                  test at screening&#xD;
&#xD;
          -  Intracranial radiation therapy within 14 days prior to SRS&#xD;
&#xD;
          -  Extracranial radiation therapy within the last 14 days prior to baseline visit&#xD;
&#xD;
          -  Treatment with strong CYP3A4/5 inhibitors (e.g. ketoconazole) and inducers (e.g.&#xD;
             phenytoin, carbamazepine). (anticonvulsant levetiracetam is allowed; patient should be&#xD;
             stable on levetiracetam for 2 weeks)&#xD;
&#xD;
          -  Unresolved toxicity of National Cancer Institute Common Terminology Crite-ria for&#xD;
             Adverse Events, version 4.0 (NCI v4.0) [NCI, 2009] Grade 2 or higher from previous&#xD;
             anti-cancer therapy, except alopecia.&#xD;
&#xD;
          -  Conditions that will interfere significantly with the absorption of drugs (e.g.&#xD;
             Colitis ulcerosa)&#xD;
&#xD;
          -  Inability to undergo MRI secondary to:&#xD;
&#xD;
               -  Metal,&#xD;
&#xD;
               -  Claustrophobia, or&#xD;
&#xD;
               -  Gadolinium contrast allergy&#xD;
&#xD;
          -  Previous malignancies active within the last 3 years, with the exception of locally&#xD;
             curable cancers that have been treated to complete remis-sion or untreated stage I&#xD;
             chronic lymphoid leukemia.&#xD;
&#xD;
          -  Unwillingness or inability to comply with study and follow-up procedures&#xD;
&#xD;
          -  Known hypersensitivity to any of the excipients of cobimetinib and vemuraf-enib&#xD;
&#xD;
          -  The following foods/supplements are prohibited at least 7 days prior to initia-tion of&#xD;
             and during study treatment:&#xD;
&#xD;
               -  St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)&#xD;
&#xD;
               -  Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)&#xD;
&#xD;
          -  Patient is included in another interventional trial&#xD;
&#xD;
          -  Use of any investigational or non-registered product within 4 weeks prior to baseline&#xD;
             visit&#xD;
&#xD;
          -  Woman of childbearing age with the exception they meet at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Post-menopausal,&#xD;
&#xD;
               -  Sterilization,&#xD;
&#xD;
               -  Consistently &amp; correct application of contraceptives (Pearl Index &lt; 1%),&#xD;
&#xD;
               -  sexual abstinence, or&#xD;
&#xD;
               -  vasectomy of the partner&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History, risk factor or retinal pathology that increases the risk of retinal vein&#xD;
             occlusion (RVO) or central serous retinopathy (CSR): evidence of retinal pathology&#xD;
             that is considered a risk factor for RVO or CSR, or a history of retinal detachment,&#xD;
             central serous chorioretinopathy or reti-nal vein thrombosis. The risk factors for RVO&#xD;
             are listed below:&#xD;
&#xD;
               -  Uncontrolled glaucoma with intraocular pressures &gt; 21 mm Hg,&#xD;
&#xD;
               -  Serum cholesterol ≥ Grade 2 (≥ 7.75 mmol/L),&#xD;
&#xD;
               -  Hypertriglyceridemia ≥ Grade 2 (≥ 3.42 mmol/L), Hyperglycemia (fasting) ≥ Grade 2&#xD;
                  (≥ 8.9 mmol/L).&#xD;
&#xD;
          -  History of clinically significant cardiac dysfunction including:&#xD;
&#xD;
               -  Myocardial infarction,&#xD;
&#xD;
               -  Severe/unstable angina pectoris,&#xD;
&#xD;
               -  Symptomatic congestive heart failure (NYHA stage ≥ 2),&#xD;
&#xD;
               -  cerebrovascular accident or transient ischemic attack within the previous 6&#xD;
                  months,&#xD;
&#xD;
               -  History of congenital long QT syndrome or mean QTcF &gt; 450 msec or uncorrectable&#xD;
                  electrolyte abnormalities,&#xD;
&#xD;
               -  Hypertension &gt; Grade 2 not controlled by medications&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; 50%, or&#xD;
&#xD;
               -  Uncontrolled arrhythmias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedegund Meier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Technische Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruprecht-Karls-University of Heidelberg, Faculty of Medicine</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls University of Tübingen, University Medical Center</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiosurgery</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>MEK inhibitor</keyword>
  <keyword>Vemurafenib</keyword>
  <keyword>Cobimetinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of the primary objective, the data might be provided to interested scientists on request (e.g. for meta-analyses or other scientific research) in an anonymized way within 5 years (according to the General Data Protection Regulation), provided that the sponsor and the coordinating principal investigators have given their prior written consent.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>within 5 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

